Quality of Life Outcomes Associated with Variable Posttransplant Prednisone Dosing Regimens

1996 ◽  
Vol 6 (2) ◽  
pp. 64-68 ◽  
Author(s):  
Donna K Hathaway ◽  
Rebecca P Winsett ◽  
E Jean Milstead ◽  
Mona N Wicks ◽  
A Osama Gaber
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Low Dose ◽  
Standard Dose ◽  
Graft Function ◽  
Transplant Recipients ◽  
Life Outcomes ◽  
Dosing Regimens ◽  
Dose Prednisone

Prednisone tapering has become more common in the management of transplant recipients. Benefits of this practice, however, must be weighed against the risks. This study identified outcomes associated with variable low dose prednisone protocols. The study sample included 98 kidney and kidney-pancreas transplant recipients 1 year after transplant. Graft function, side effects of steroid therapy, and quality of life were recorded on patients receiving 0 (n=5), 1 to 5 (n=4), 5 to 7.5 (n=5), 7.5 to 10 (n=21), and greater than 10 mg/d prednisone (n=63). Despite the fact that patients were assigned to the low dose groups because they were at risk for or already experiencing steroid induced side effects, the low dose groups presented side effect and quality of life profiles similar to or better than those of the standard dose group.

Assessing Quality-of-Life Outcomes in Organ Transplant Recipients: Progress and Priorities

2003 ◽  
Vol 13 (2_suppl) ◽  
pp. 1-2
Author(s):  
Donna Hathaway ◽  
Mark L. Barr ◽  
R. Mark Ghobrial ◽  
James Rodrigue ◽  
Sharlyn Bogner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Organ Transplant ◽  
Transplant Recipients ◽  
Life Outcomes ◽  
Organ Transplant Recipients ◽  
Quality Of Life Outcomes

The study of the treatment efficacy in metastatic castration-resistant prostate cancer of low dose abiraterone with food.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17571-e17571
Author(s):  
Kanta Makphanchareonkit ◽  
Thitiya Sirisinha Dejthevaporn ◽  
Dittapol Muntham ◽  
Phichai Chansriwong
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Adverse Events ◽  
Low Dose ◽  
Standard Dose ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Psa Response

e17571 Background: Abiraterone acetate and prednisolone (AAP) + ADT has been approved for treatment metastatic castration-resistant prostate cancer (CRPC) in the standard dose 1,000 mg with fasting state. Data in Ramathibodi hospital showed patients who had treated with standard dose of Abiraterone acetate (AA); had PSA response 47.83%. Previous studies showed using low dose AA of 250 mg with food had the non-inferiority results in efficacy. AA was not be reimbursed in Thailand, so the ability to use a highly effective drug at a quarter of the dose, could help in patient accessibility to cancer treatments. We sought to test the hypothesis that low-dose AA with food would have the comparable activity in Thai CRPC patients in both of the pre-Docetaxel and post Docetaxel treatment groups, and exploring the quality of life (QOL) of these patients. Methods: An observational cohort enrolled newly diagnosed metastasis CRPC at Ramathibodi hospital from 1st Jan 2019 to 31st Dec 2019. Patients were assigned to AA (250mg) with actual daily life meal. We collected the data of serum PSA and the adverse events every 4 weeks for 4 months. The QOL data was collected with the EuroQoL (EQ-5D) questionnaire which were done at baseline and every 4 weeks. The primary end point was PSA response that defined as PSA decreased ≥ 50% from PSA level at baseline. The secondary endpoint were the depth of PSA change, QOL and adverse events by using Fisher's exact test and T-test. Results: 21 patients were enrolled. At 12 weeks, there were 11 patients (52.38%) achieved 50% PSA response and 6 patients (28.57%) achieved 90% PSA response. The adverse events occurred 23.8%, and mostly were mild grade. The adverse events were comparable with the historical data in standard dose of AA. Low dose AA has significantly shown the improvement in quality of life from baseline (p < 0.001), and especially the significant improvement in pre-Docetaxel subgroup. Conclusions: Low-dose AA with food has good efficacy in PSA response, adverse events and QOL. Moreover, low dose AA shows more efficacy especially in pre-Docetaxel mCRPC patients. Low dose AA may be helping in reducing cost of cancer care, enabling in delivering affordable cancer care and increasing value of treatment.

Assessing quality-of-life outcomes in organ transplant recipients: progress and priorities

2003 ◽  
Vol 13 (Supplement 2) ◽  
pp. 1-2 ◽  
Author(s):  
Donna Hathaway ◽  
Mark Barr ◽  
R. Ghobrial ◽  
James Rodrigue ◽  
Sharlyn Bogner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Organ Transplant ◽  
Transplant Recipients ◽  
Life Outcomes ◽  
Organ Transplant Recipients ◽  
Quality Of Life Outcomes

Long-term Health Status and Quality of Life Outcomes of Lung Transplant Recipients

CHEST Journal ◽  
1995 ◽  
Vol 108 (6) ◽  
pp. 1587-1593 ◽  
Author(s):  
Cynthia R. Gross ◽  
Kay Savik ◽  
R. Morton Bolman ◽  
Marshall I. Hertz
Keyword(s):  
Quality Of Life ◽  
Health Status ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Life Outcomes ◽  
Quality Of Life Outcomes ◽  
Lung Transplant Recipients

scholarly journals Quality of life outcomes after low dose‐rate brachytherapy for localized prostate cancer: Current status and future perspectives

2019 ◽  
Vol 26 (12) ◽  
pp. 1099-1105
Author(s):  
Yasukiyo Murakami ◽  
Takefumi Satoh ◽  
Hideyasu Tsumura ◽  
Ken‐ichi Tabata ◽  
Kazumasa Matsumoto ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Dose Rate ◽  
Low Dose ◽  
Current Status ◽  
Life Outcomes ◽  
Future Perspectives ◽  
Low Dose Rate ◽  
Low Dose Rate Brachytherapy

Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats

2021 ◽  
pp. 1098612X2110670
Author(s):  
Samuel J Keepman ◽  
MacKenzie A Pellin
Keyword(s):  
Quality Of Life ◽  
Low Dose ◽  
Standard Dose ◽  
Maximum Tolerated Dose ◽  
Pain Scores ◽  
Starting Dose ◽  
Safety Studies ◽  
Inflammatory Drugs ◽  
Tumor Measurements

Objectives Non-steroidal anti-inflammatory drugs (NSAIDs) are infrequently utilized in cats due to concern for renal compromise; however, recent studies demonstrate tolerability of low dose meloxicam. Toceranib phosphate is used to treat several feline cancers and is well tolerated. This study aimed to determine the tolerability and adverse event profile of combined toceranib and low dose meloxicam in cancer-bearing cats. Secondary goals involved assessing anticancer tumor efficacy and impact upon quality of life and analgesia. Methods Cats with any cancer not involving the kidneys were eligible. The study adopted a conventional 3 + 3 dose escalation design. Toceranib was administered every other day at a standard dose with meloxicam administered in an escalating fashion in subsequent cohorts, at a starting dose of 0.01 mg/kg on opposite days to toceranib, up to a maximum of 0.02 mg/kg daily, based upon previous safety studies. Laboratory work, blood pressure, tumor measurements, pain score and client-completed quality-of-life surveys were recorded every 2–4 weeks during the 12-week study period. Results Twenty-one cats were enrolled. When combined with toceranib, a meloxicam dose of 0.02 mg/kg q24h was safe and well tolerated, with no cats being withdrawn due to adverse events from the drug combination. The majority of cats demonstrated clinical benefit with stable to mildly improved tumor measurements, quality of life and pain scores. Conclusions and relevance Low dose meloxicam combined with toceranib is safe and well tolerated in cancer-bearing cats. Continued patient recruitment and data collection are needed to determine the maximum tolerated dose of meloxicam. The results of our study will guide further phase II/III trials.

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

1989 ◽  
Vol 7 (5) ◽  
pp. 590-597 ◽  
Author(s):  
I Tannock ◽  
M Gospodarowicz ◽  
W Meakin ◽  
T Panzarella ◽  
L Stewart ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Prostatic Cancer ◽  
Low Dose ◽  
Serum Testosterone ◽  
Well Being ◽  
Response To Treatment ◽  
Adrenal Androgens ◽  
Dose Prednisone

Thirty-seven men with symptomatic bone metastases from prostate cancer that had progressed following earlier treatment with estrogens and/or orchidectomy were treated with low-dose prednisone (7.5 to 10 mg daily). The rationale for this treatment was that some patients might still have hormone-sensitive disease that was stimulated by weak androgens of adrenal origin, and that these androgens could be suppressed by prednisone through its negative feedback on secretion of adrenocorticotrophic hormone (ACTH). Response to treatment was assessed by requirement for analgesics, by the McGill-Melzack pain questionnaire, and by a series of 17 linear analog self-assessment (LASA) scales relating to pain and to various aspects of quality of life. Fourteen patients (38%) had improvement in indices used to assess pain at 1 month after starting prednisone, and seven patients (19%) maintained this improvement for 3 to 30 months (median, 4 months). Reduction in pain was associated with improvement in other dimensions of quality of life, and in the scale for overall well-being. Prednisone treatment led to a decrease in the concentration of serum testosterone in seven of nine patients where it was not initially suppressed below 2 nmol/L, and caused a decrease in serum levels of androstenedione and dehydroepiandrosterone sulfate in more than 50% of patients. Symptomatic response was associated with a decrease in serum concentration of adrenal androgens. We conclude that (1) low-dose prednisone may cause useful relief of pain in some patients with advanced prostatic cancer; (2) relief of pain was associated with suppression of adrenal androgens; and (3) measures of pain and quality of life can be used to assess possible benefits of systemic therapy in patients with metastatic prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document